State lawmakers send abortion bill goes back to committee
Indiana House Republicans are taking the unusual step of reassigning an abortion bill to the same panel that narrowly approved it last week.
Health Care & Life Sciences
Articles
As pricing criticism mounts, Lilly, other drugmakers roll out pay for performance
In Lilly’s partnership with Harvard Pilgrim Health Care, the not-for-profit insurer gets additional rebates if fewer patients using Lilly's diabetes treatment Trulicity meet blood sugar goals than expected.
Trump health pick from Indiana says Medicaid needs major overhaul
Indiana health care consulting executive Seema Verma on Thursday testified before the Senate Finance Committee on her nomination to lead the Centers for Medicare and Medicaid Services, or CMS.
Judge blocks Cigna from scuttling $48 billion deal with Anthem
Indianapolis-based Anthem Inc. on Wednesday won a court ruling blocking Cigna Corp. from terminating a proposed merger between the health insurers until a judge could weigh arguments over the faltering deal at an April 10 hearing.
Merck stops Alzheimer’s study after ‘no chance’ of benefit
Merck & Co. on Tuesday announced that it will end a study of its once-promising Alzheimer’s disease drug in patients with mild-to-moderate forms of the condition, just three months after Eli Lilly and Co. announced its own setback in a field that’s been littered with failures.
Anthem sues to block Cigna from terminating $48B merger
In the lawsuit, Anthem blasted Cigna, accusing it of repeated efforts to sabotage their proposed merger.
Cigna seeks to terminate merger with Anthem, sues insurer for $13B
Indianapolis-based Anthem responded almost immediately Tuesday by saying Cigna does not have the right to cancel the deal.
Aetna gives up on $34B Humana deal, will pay $1B breakup fee
The Humana-Aetna deal was one of two mergers that would have reshaped the U.S. health insurance landscape. Both were rejected by federal judges as anticompetitive. Anthem hasn't given up on its deal—a $48 billion pact to acquire Cigna—and is pressing ahead with an appeal.
Indy-founded drug firm lands nearly $23M to fight rare disease
Two local men who have been working on a potential blockbuster treatment for a rare and debilitating disease are hopeful that a major injection of venture capital will provide the boost needed to move the drug to market—even if it means sweeping changes for their company.
After megadeals blocked, health insurers plotting next moves
Anthem filed a notice of appeal on Thursday after a federal judge blocked its $48 billion deal to buy Cigna Corp.
Dying patients have Pence’s backing on ‘right to try’ policy
Vice President Mike Pence may have just picked another fight with pharmaceutical companies—one that doesn’t involve drug prices.
Anthem vows to appeal ruling blocking $48B Cigna purchase
While Anthem said it was “significantly disappointed” by the judge’s order and would seek an expedited appeal, Cigna said only that it “intends to carefully review the opinion and evaluate its options in accordance with the merger agreement.”
Anthem’s $48B bid for Cigna blocked by judge as anticompetitive
The deal, along with Aetna Inc.’s proposed tie-up with Humana Inc., which was blocked last month, was set to reduce the ranks of big U.S. health insurers to three from five and make Anthem the largest by membership.
Local health care facility with 87 employees shutting down
The closure of an Indianapolis residential care facility is expected to result in the loss of 87 jobs, but some of the workers might be able to land employment at the same company.
Holcomb’s HIP 2.0 waiver likely to sail through Washington
The Trump administration and its pick to lead the Centers for Medicare & Medicaid Services are likely to champion the approach behind HIP 2.0—a Medicaid expansion that requires those receiving insurance coverage to have "skin in the game" by contributing financially.
Lilly CEO encouraged by Trump meeting, concerned about Obamacare
Eli Lilly and Co. CEO Dave Ricks said he was encouraged by President Donald Trump’s understanding of the complexities of drug development, yet he’s concerned about risks the industry may face in a fresh overhaul of the U.S. health-care system.
Anthem quarterly profit tops expectations; insurer says it’s ‘well positioned’ for 2017
The company’s quarterly earnings announcement did not mention any new developments in the insurer’s pending, $54 billion acquisition of Cigna—which is under review by a federal judge.
Trump spoils pharma chiefs with no more bad news on drug pricing
For drugmakers, including Indianapolis-based Eli Lilly and Co., a meeting Tuesday with President Donald Trump was a dose of happy pills.
Lawsuit says NCAA, Riddell didn’t educate on head injuries
The NCAA and helmet maker Riddell are defendants in separate class-action lawsuits alleging they failed to protect football players from long-term head injuries and didn't educate them about the risks.
UPDATE: Trump tells drugmakers, including Lilly, their prices are ‘astronomical’
President Trump took Big Pharma to task on pricing but also promised to ease regulations and find ways to speed medicines to market, which triggered a surge in the sector’s share prices.